Maurizia R Brunetto

Summary

Affiliation: U.O. Gastroenterologia ed Epatologia
Country: Italy

Publications

  1. ncbi Treatment of chronic hepatitis B: from research to clinical practice via the consensus conferences
    M R Brunetto
    U O Gastroenterologia e Epatologia, Azienda Ospedaliera Pisana, Via Paradisa 2, 56124 Cisanello, Pisa, Italy
    Curr Pharm Des 10:2063-75. 2004
  2. ncbi Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon
    Maurizia Rossana Brunetto
    U.O. Gastroenterologia ed Epatologia, Azienda Ospedaliera, Universitaria Pisana, Pisa, Italy
    J Hepatol 39:S164-7. 2003
  3. ncbi Personalized therapy in chronic viral hepatitis
    Maurizia Rossana Brunetto
    Gastroenterology and Hepatology Unit, University Hospital of Pisa, Via Paradisa 2, 56124 Cisanello, Pisa, Italy
    Mol Aspects Med 29:103-11. 2008
  4. ncbi Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis
    Maurizia Rossana Brunetto
    UO Epatologia, Azienda Ospedaliero Universitaria Pisana, 56100 Pisa, Italy
    World J Gastroenterol 15:531-7. 2009
  5. ncbi Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers
    Maurizia Rossana Brunetto
    Hepatology Unit, University Hospital of Pisa, University of Pisa, Pisa, Italy
    Gastroenterology 139:483-90. 2010
  6. ncbi New approaches to optimize treatment responses in chronic hepatitis B
    Maurizia R Brunetto
    Hepatology Unit, University Hospital of Pisa, Pisa, Italy
    Antivir Ther 15:61-8. 2010
  7. ncbi Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study
    Maurizia Rossana Brunetto
    U O Gastroenterologia ed Epatologia, Spedali Riuniti di Santa Chiara, Via Paradisa n 2 Cisanello, 56124 Pisa, Italy
    J Hepatol 36:263-70. 2002
  8. ncbi A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy
    Piero Colombatto
    UO Gastroenterologia ed Epatologia Ospedaliera, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
    Antivir Ther 11:197-212. 2006
  9. ncbi Liver stiffness, a non-invasive marker of liver disease: a core study group report
    Ferruccio Bonino
    Digestive and Liver Disease Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy
    Antivir Ther 15:69-78. 2010
  10. ncbi Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells
    P Colombatto
    UO Epatologia SSN, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
    Clin Pharmacol Ther 84:212-5. 2008

Collaborators

Detail Information

Publications26

  1. ncbi Treatment of chronic hepatitis B: from research to clinical practice via the consensus conferences
    M R Brunetto
    U O Gastroenterologia e Epatologia, Azienda Ospedaliera Pisana, Via Paradisa 2, 56124 Cisanello, Pisa, Italy
    Curr Pharm Des 10:2063-75. 2004
    ..In perspectives, currently available molecular and immunologic tools and modelling of viral dynamics will help to address the therapy issue with more complex, efficacious and individually tailored treatment schedules...
  2. ncbi Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon
    Maurizia Rossana Brunetto
    U.O. Gastroenterologia ed Epatologia, Azienda Ospedaliera, Universitaria Pisana, Pisa, Italy
    J Hepatol 39:S164-7. 2003
  3. ncbi Personalized therapy in chronic viral hepatitis
    Maurizia Rossana Brunetto
    Gastroenterology and Hepatology Unit, University Hospital of Pisa, Via Paradisa 2, 56124 Cisanello, Pisa, Italy
    Mol Aspects Med 29:103-11. 2008
    ..We provide a concise review of the potentials of this approach in clinical practice...
  4. ncbi Bio-mathematical models of viral dynamics to tailor antiviral therapy in chronic viral hepatitis
    Maurizia Rossana Brunetto
    UO Epatologia, Azienda Ospedaliero Universitaria Pisana, 56100 Pisa, Italy
    World J Gastroenterol 15:531-7. 2009
    ....
  5. ncbi Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers
    Maurizia Rossana Brunetto
    Hepatology Unit, University Hospital of Pisa, University of Pisa, Pisa, Italy
    Gastroenterology 139:483-90. 2010
    ..We studied whether hepatitis B surface antigen (HBsAg) serum levels (HBsAgsl) quantification may contribute to diagnosis of HBV phases in untreated hepatitis B e antigen-negative genotype D asymptomatic carriers...
  6. ncbi New approaches to optimize treatment responses in chronic hepatitis B
    Maurizia R Brunetto
    Hepatology Unit, University Hospital of Pisa, Pisa, Italy
    Antivir Ther 15:61-8. 2010
    ..In this article, we review the current approaches to optimize treatment response to nucleoside/nucleotide analogue- and interferon-based therapies for chronic hepatitis B...
  7. ncbi Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study
    Maurizia Rossana Brunetto
    U O Gastroenterologia ed Epatologia, Spedali Riuniti di Santa Chiara, Via Paradisa n 2 Cisanello, 56124 Pisa, Italy
    J Hepatol 36:263-70. 2002
    ....
  8. ncbi A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy
    Piero Colombatto
    UO Gastroenterologia ed Epatologia Ospedaliera, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
    Antivir Ther 11:197-212. 2006
    ..3 log10, P = 0.039). In conclusion, peg-IFN-alpha2a, in spite of having direct antiviral activity lower than that of 3TC, achieved a comparable reduction of infected hepatocytes, possibly because of a higher infected cell clearance rate...
  9. ncbi Liver stiffness, a non-invasive marker of liver disease: a core study group report
    Ferruccio Bonino
    Digestive and Liver Disease Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy
    Antivir Ther 15:69-78. 2010
    ..The group concluded that FibroScan(®) is a valuable, non-invasive technique and have developed a consensus report form for registering transient elastography results. In this article, we report the findings of the study group...
  10. ncbi Early and accurate prediction of Peg-IFNs/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells
    P Colombatto
    UO Epatologia SSN, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
    Clin Pharmacol Ther 84:212-5. 2008
    ..Overall, the duration of therapy would have been 49 months less than that suggested by the most recent algorithms based on a rapid virological response (RVR) at week 4...
  11. ncbi Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs
    Luisa Novellino
    Hepatology Unit and Liver Physiopathology Laboratory, University Hospital of Pisa, Pisa, Italy
    PLoS ONE 7:e31952. 2012
    ....
  12. ncbi Diagnostic markers of chronic hepatitis B infection and disease
    Ferruccio Bonino
    Digestive and Liver Disease Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy
    Antivir Ther 15:35-44. 2010
    ..In this article, we review current opinions on the appropriate use of diagnostic procedures, answering some important questions for the clinician, such as why, how, when and in whom they might best be used...
  13. ncbi Treatment of patients with chronic hepatitis C and cirrhosis
    F Bonino
    Gastroenterologia and Epatologia, Spedali Riuniti di Santa Chiara, Azienda Ospedaliera Pisana, Cisanello, Pisa, Italy
    J Hepatol 31:197-200. 1999
    ..Prospective, randomized clinical trials should be performed after stratification of these patients for stage and cofactors of liver disease...
  14. ncbi Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases
    B Coco
    UO Gastroenterologia ed Epatologia Ospedaliera, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
    J Viral Hepat 14:360-9. 2007
    ....
  15. ncbi Hepatitis C virus infection: early diagnosis and identification of response to antiviral therapy
    F Bonino
    Azienda Ospedaliera Universitaria Pisana, Via Paradisa 2, 56124 Cisanello Pisa, Italy
    Expert Rev Mol Diagn 1:310-4. 2001
    ..Some of the current issues and perspectives involved in detection and quantification of viral load during the incubation phase of infection and monitoring the early phase of antiviral therapy are discussed...
  16. ncbi Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
    F Bonino
    University of Pisa and Foundation IRCCS, Policlinico di Milano, Milan, Italy
    Gut 56:699-705. 2007
    ..The effect of pre-treatment factors on post-treatment responses was investigated...
  17. ncbi Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos(t)ide analogues during lamivudine treatment
    F Moriconi
    UO Gastroenterologia ed Epatologia Ospedaliera, University Hospital of Pisa, Pisa, Italy
    J Antimicrob Chemother 60:341-9. 2007
    ..We studied the impact of hepatitis B virus (HBV) polymerase/reverse transcriptase (Pol/Rt) heterogeneity on adefovir rescue therapy in 34 consecutive chronic hepatitis B patients with viral breakthrough during lamivudine monotherapy...
  18. ncbi Increasing serum levels of IgM anti-HCV are diagnostic of recurrent hepatitis C in liver transplant patients with ALT flares
    P Ciccorossi
    U.O. Gastroenterologia e Epatologia, , Via Paradisa 2, Ospedale Cisanello, 56124 Pisa, Italy
    J Viral Hepat 10:168-73. 2003
    ..9% diagnostic accuracy...
  19. ncbi Validation and comparison of different PCR-based methods for detection of hepatitis B virus precore region mutants
    D Flichman
    UO Gastroenterologia ed Epatologia, Azienda Ospedaliero Universitaria Pisana, Via Paradisa 2, 56124 Pisa, Italy
    J Virol Methods 129:64-74. 2005
    ..In conclusion, an accurate characterization of HBV precore heterogeneity should be warranted by a careful choice of the most appropriate assay according to the aim of the study...
  20. ncbi Diagnosis and monitoring of hepatitis virus infection in liver transplant patients
    A M Maina
    Department of Gastroenterology, University Hospital of Pisa, Via Paradisa 2, 56124 Pisa, Italy
    Transplant Proc 35:1025-7. 2003
  21. ncbi Impact of antiviral treatment on recurrence of hepatitis B virus infection and disease
    P Ciccorossi
    U.O. Gastroenterologia e Epatologia, , Pisa, Italy
    Transplant Proc 35:1028-9. 2003
  22. ncbi Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview
    Ferruccio Bonino
    Direzione Scientifica, Ospedale Maggiore di Milano, Policlinico, IRCCS, Via Francesco Sforza, 28, 20122 Milan, Italy
    J Hepatol 39:S160-3. 2003
  23. ncbi Recent progress and new trends in the treatment of hepatitis B
    Alfredo Alberti
    Department of Internal Medicine, University of Padua, Padua, Italy
    J Med Virol 67:458-62. 2002
    ..10%, P = 0.045), but not in Milan (7 vs. 10%, P = ns)...
  24. ncbi Severe liver disease is caused by HBV rather than HCV in children with hematological malignancies
    Manal H El-Sayed
    Pediatric Department, Hematology Oncology Division, Children s Hospital, Ain Shams University, Abassyia, Cairo, Egypt
    Hematol J 4:321-7. 2003
    ..FHF occurred in HBsAg/HBV-DNA(+) children following i.v. methotrexate. Early recognition of hepatic dysfunction in HBV carriers is essential in order to reduce incidence of life-threatening complications...
  25. ncbi Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance
    Maurizia Rossana Brunetto
    J Hepatol 46:756-8. 2007
  26. ncbi Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase
    Piero Colombatto
    UO Gastroenterologia ed Epatologia, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy
    Antivir Ther 8:519-30. 2003
    ..All three relapsers received interferon monotherapy. CONCLUSION: The analysis of infected cells dynamics using the new model might be useful to tailor treatment duration in patients with combination therapy...